Oxford Gene Technology (OGT) announces the appointment of David Owen to the OGT board as a non-executive director
After graduating with a PhD in pharmacology, David Owen worked in R and D in the pharmaceutical industry for 20 years (Sandoz, and SmithKline and French).
He went on to lead technology driven licensing agreements for SmithKline and French as group director for compound and technology acquisitions.
In 1990 he joined the MRC as CEO of MRC Technology, and led technology transfer activities in patenting, licensing technologies, creating new start-up companies and generation of revenues.
In June 2001 Owen was awarded the OBE for services to medical research and technology transfer.
He is currently non-executive chairman of Abcellute and the Cardiff Partnership Fund, co-chairman of EMBL Enterprise Management, and is a past president of the Association of European Science and Technology Transfer Professionals.
Owen said: "I am delighted and very flattered to be invited to participate in the business of OGT.
"The company's leading technologies are fundamental tools in many facets of molecular biology research and thereby facilitate key advances in bioscience knowledge and understanding.
"I look forward to joining fellow directors in building on the current success of OGT and to help develop the company further.
Professor Sir Ed Southern, OGT's chairman, said: "I am pleased to welcome David to the OGT board.
"He has had a distinguished career in pharmaceutical research and technology transfer and will bring a wealth of experience".
Oxford Gene Technology (OGT) is a privately owned company founded in 1995 by Professor Sir Edwin Southern.
The mission of the company is to develop advanced molecular tools for biologists and to make them widely available through licensing and service activities.
